Quest Diagnostics (DGX)
NYSE: DGX
· Real-Time Price · USD
179.52
-1.44 (-0.80%)
At close: Oct 03, 2025, 3:59 PM
181.31
1.00%
After-hours: Oct 03, 2025, 06:22 PM EDT
Quest Diagnostics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Information Services Business Revenue | 2.7B | 2.59B | 2.56B | 2.43B | 2.33B | 2.3B | 2.22B | 2.23B | 2.27B | 2.26B | 2.27B | 2.92B | 2.71B | 1.76B | 1.74B | 1.88B | 1.87B | 1.81B | 1.81B | 1.83B | 1.8B | 1.85B | 1.85B | 1.81B | 1.8B | 1.81B | 1.76B |
| Diagnostic Information Services Business Revenue Growth | +4.25% | +1.29% | +5.32% | +4.03% | +1.52% | +3.47% | -0.31% | -1.76% | +0.40% | -0.26% | -22.48% | +7.86% | +53.57% | +1.15% | -7.09% | +0.27% | +3.31% | +0.11% | -1.36% | +1.77% | -2.54% | -0.27% | +2.37% | +0.67% | -0.50% | +3.02% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 480M | 476M | 466M | 448M | 406M | 436M | 402M | 380M | 416M | 439M | 563M | 464M | 422M | 425M | 464M | 427M | 429M | 407M | 447M | 396M | 360M | 347M | 349M | 362M | 362M | 384M | 356M | 354M | 351M | 363M | 453M | 423M | 437M | 437M | 400M | 409M | 430M | 442M | 429M | 402M | 429M | 419M |
| Selling, General, and Administrative Revenue Growth | +0.84% | +2.15% | +4.02% | +10.34% | -6.88% | +8.46% | +5.79% | -8.65% | -5.24% | -22.02% | +21.34% | +9.95% | -0.71% | -8.41% | +8.67% | -0.47% | +5.41% | -8.95% | +12.88% | +10.00% | +3.75% | -0.57% | -3.59% | 0.00% | -5.73% | +7.87% | +0.56% | +0.85% | -3.31% | -19.87% | +7.09% | -3.20% | 0.00% | +9.25% | -2.20% | -4.88% | -2.71% | +3.03% | +6.72% | -6.29% | +2.39% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |